Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population-Reference-Cited by-同舟云学术

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

Published:2009-09 Issue:9 Volume:19 Page:704-709
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Tassaneeyakul Wichittra,Jantararoungtong Thawinee,Chen Pei,Lin Pao-Yu,Tiamkao Somsak,Khunarkornsiri Usanee,Chucherd Pachadaporn,Konyoung Parinya,Vannaprasaht Suda,Choonhakarn Charoen,Pisuttimarn Pornrith,Sangviroon Alisara,Tassaneeyakul Wongwiwat

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference23 articles.

1. Adverse drug reactions: types and treatment options;Riedl;Am Fam Physician,2003

2. Clinical heterogeneity of drug hypersensitivity;Roujeau;Toxicology,2005

3. Life-threatening acute adverse cutaneous drug reactions;Wolf;Clin Dermatol,2005

4. Severe cutaneous adverse reactions to drugs;Roujeau;N Engl J Med,1994

5. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients;Chan;Arch Dermatol,1990

Cited by 342 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stevens–Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management;Chinese Medical Journal;2024-09-05

2. Endogamy and high prevalence of deleterious mutations in India: evidence from strong founder events;2024-08-29

3. Risk factors for drug hypersensitivity reactions in children;Italian Journal of Pediatrics;2024-07-15

4. Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population;Biomarker Research;2024-05-03

5. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease;Medical Science Monitor;2024-05-01